Group 1 - The core viewpoint emphasizes the importance of improving reproductive support policies to promote high-quality population development, with assisted reproductive technology (ART) playing a crucial role [1] - Recent policies have included suitable assisted reproductive technologies in medical insurance reimbursement, providing financial relief for patients with reproductive obstacles [2][3] - The integration of ART into medical insurance not only alleviates economic burdens but also reduces psychological stress for patients, encouraging more families to seek treatment [2] Group 2 - The development of ART has undergone three iterations since the first test-tube baby was born in China in 1988, with each generation addressing different reproductive issues [4] - The first generation focuses on in vitro fertilization and embryo transfer, the second on intracytoplasmic sperm injection for male infertility, and the third on genetic screening to reduce risks of miscarriage and birth defects [4][5] - Patients are advised to choose the appropriate ART based on their specific conditions, such as opting for conventional IVF for tubal infertility or genetic screening for chromosomal abnormalities [4] Group 3 - Weight management is highlighted as a significant factor affecting the success of ART, with obesity potentially leading to reproductive endocrine dysfunction and complications during pregnancy [6][7] - Patients seeking ART are encouraged to achieve a stable weight through dietary and exercise adjustments before undergoing treatment to ensure safety during pregnancy [7] - The integration of artificial intelligence in reproductive medicine is being explored to enhance treatment outcomes, including the development of ovarian function prediction software and improved embryo selection processes [6][8]